BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

727 related articles for article (PubMed ID: 25663597)

  • 1. Prognostic Role of Conversion Surgery for Unresectable Gastric Cancer.
    Fukuchi M; Ishiguro T; Ogata K; Suzuki O; Kumagai Y; Ishibashi K; Ishida H; Kuwano H; Mochiki E
    Ann Surg Oncol; 2015 Oct; 22(11):3618-24. PubMed ID: 25663597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of conversion gastrectomy following docetaxel, cisplatin, and S-1 therapy in potentially resectable stage IV gastric cancer.
    Kinoshita J; Fushida S; Tsukada T; Oyama K; Okamoto K; Makino I; Nakamura K; Miyashita T; Tajima H; Takamura H; Ninomiya I; Ohta T
    Eur J Surg Oncol; 2015 Oct; 41(10):1354-60. PubMed ID: 26028256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of preoperative S-1 plus cisplatin followed by surgery for initially unresectable locally advanced gastric cancer.
    Inoue K; Nakane Y; Kogire M; Fujitani K; Kimura Y; Imamura H; Tamura S; Okano S; Kwon AH; Kurokawa Y; Shimokawa T; Takiuchi H; Tsujinaka T; Furukawa H
    Eur J Surg Oncol; 2012 Feb; 38(2):143-9. PubMed ID: 22154885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of stage IV gastric cancer with induction chemotherapy using S-1 and cisplatin followed by curative resection in selected patients.
    Saito M; Kiyozaki H; Takata O; Suzuki K; Rikiyama T
    World J Surg Oncol; 2014 Dec; 12():406. PubMed ID: 25551581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion surgery after combination chemotherapy of docetaxel, cisplatin and S-1 (DCS) for far-advanced gastric cancer.
    Mieno H; Yamashita K; Hosoda K; Moriya H; Higuchi K; Azuma M; Komori S; Yoshida T; Tanabe S; Koizumi W; Katada N; Watanabe M
    Surg Today; 2017 Oct; 47(10):1249-1258. PubMed ID: 28365892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion therapy for inoperable advanced gastric cancer patients by docetaxel, cisplatin, and S-1 (DCS) chemotherapy: a multi-institutional retrospective study.
    Sato Y; Ohnuma H; Nobuoka T; Hirakawa M; Sagawa T; Fujikawa K; Takahashi Y; Shinya M; Katsuki S; Takahashi M; Maeda M; Okagawa Y; Naoki U; Kikuch S; Okamoto K; Miyamoto H; Shimada M; Takemasa I; Kato J; Takayama T
    Gastric Cancer; 2017 May; 20(3):517-526. PubMed ID: 27553665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of neoadjuvant chemotherapy with S-1 and cisplatin for stage III gastric cancer: KUGC03.
    Okabe H; Hata H; Ueda S; Zaima M; Tokuka A; Yoshimura T; Ota S; Kinjo Y; Yoshimura K; Sakai Y;
    J Surg Oncol; 2016 Jan; 113(1):36-41. PubMed ID: 26604064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China.
    Zhu Y; Sun Y; Hu S; Jiang Y; Yue J; Xue X; Yang L; Xue L
    BMC Gastroenterol; 2017 Mar; 17(1):41. PubMed ID: 28292272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of S-1 plus Cisplatin Neoadjuvant Chemotherapy on Scirrhous Gastric Cancer.
    Kunisaki C; Makino H; Kimura J; Takagawa R; Kanazawa A; Ota M; Kosaka T; Ono HA; Akiyama H; Endo I
    Oncology; 2015; 88(5):281-8. PubMed ID: 25591954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction chemotherapy with S-1 plus cisplatin followed by surgery for treatment of gastric cancer with peritoneal dissemination.
    Okabe H; Ueda S; Obama K; Hosogi H; Sakai Y
    Ann Surg Oncol; 2009 Dec; 16(12):3227-36. PubMed ID: 19777180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic analysis of stage III gastric cancer after curative surgery according to the newest TNM classification.
    Wei J; Yao T; Wang Y; Li L; Pan C; Zhang N
    Clin Transl Oncol; 2019 Feb; 21(2):232-238. PubMed ID: 29968135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of adjuvant S-1/cisplatin chemotherapy followed by S-1-based chemoradiotherapy for D2-resected gastric cancer.
    Shim HJ; Kim KR; Hwang JE; Bae WK; Ryu SY; Park YK; Nam TK; Chung IJ; Cho SH
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):605-12. PubMed ID: 26846507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accuracy of CT staging of locally advanced gastric cancer after neoadjuvant chemotherapy: cohort evaluation within a randomized phase II study.
    Yoshikawa T; Tanabe K; Nishikawa K; Ito Y; Matsui T; Kimura Y; Hasegawa S; Aoyama T; Hayashi T; Morita S; Miyashita Y; Tsuburaya A; Sakamoto J
    Ann Surg Oncol; 2014 Jun; 21 Suppl 3():S385-9. PubMed ID: 24595801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Conversion Surgery Following S-1 plus Cisplatin or Oxaliplatin Chemotherapy for Unresectable Gastric Cancer.
    Fukuchi M; Mochiki E; Ishiguro T; Ogura T; Sobajima J; Kumagai Y; Ishibashi K; Ishida H
    Anticancer Res; 2017 Mar; 37(3):1343-1347. PubMed ID: 28314301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
    Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy of pre-operative chemotherapy with docetaxel, cisplatin, and S-1 (DCS therapy) and curative resection for gastric cancer with pathologically positive para-aortic lymph nodes.
    Oyama K; Fushida S; Kinoshita J; Makino I; Nakamura K; Hayashi H; Nakagawara H; Tajima H; Fujita H; Takamura H; Ninomiya I; Kitagawa H; Tani T; Fujimura T; Ohta T
    J Surg Oncol; 2012 May; 105(6):535-41. PubMed ID: 22006649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perioperative chemotherapy for resectable gastroesophageal cancer: a single-center experience.
    Molina R; Lamarca A; Martínez-Amores B; Gutiérrez A; Blázquez A; López A; Granell J; Álvarez-Mon M
    Eur J Surg Oncol; 2013 Aug; 39(8):814-22. PubMed ID: 23755989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma.
    Park I; Ryu MH; Choi YH; Kang HJ; Yook JH; Park YS; Kim HJ; Jung HY; Lee GH; Kim KC; Kim BS; Kang YK
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):815-23. PubMed ID: 23921575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of Survival in Patients with Resectable Gastric Cancer Treated with Preoperative Chemoradiation Therapy and Gastrectomy.
    Badgwell B; Blum M; Estrella J; Chiang YJ; Das P; Matamoros A; Fournier K; Mansfield P; Ajani J
    J Am Coll Surg; 2015 Jul; 221(1):83-90. PubMed ID: 26002780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.